Gorkem Turhan

Dr. Gorkem Turhan

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2025 in Genes
Verified
Journal Article
Open access
PDF file
KCKÜBRA CANASLAN
KÜBRA CANASLAN
EEEMRE EKEN
EMRE EKEN
MBMehmet Bilici
Mehmet Bilici
FBFahriye merve Balcıoğlu
Fahriye merve Balcıoğlu
BOBanu Ozturk
Banu Ozturk
AKAziz Karaoğlu
Aziz Karaoğlu
Background/Objectives: Genomic profiling guides treatment in metastatic non-small-cell lung cancer (mNSCLC), yet country-level data from Türkiye remain limited. Methods: We retrospectively analyzed consecutive patients with mNSCLC diagnosed between January 2018 and March 2025 across tertiary centers in all seven regions. Variables included demographics, smoking, histology, testing modality (single-gene vs. next-generation sequencing [NGS]), targetable genomic alterations (TGAs) and co-mutations, and programmed death-ligand 1 (PD-L1) tumor proportion score. Results: Among 1023 patients (mean age 64 years; 76.4% male), tobacco exposure was frequent (mean 42.1 pack-years); 16.9% were never-smokers. NGS use increased over time, exceeding 90% by 2025. TGAs were detected in 28.3% (EGFR 16.0%, ALK 5.0%, KRAS G12C 2.6%, BRAF V600E 3.2%; ROS1, MET exon 14, HER2, NTRK ≤ 2.5%; no RET). EGFR alterations occurred in 19% of non-squamous carcinomas and 6% of squamous cell carcinomas (SCCs), suggesting an intermediate East–West pattern. Among NGS-tested samples, TP53 was the most frequent co-mutation (33.1%), followed by alterations in CDKN2A, PIK3CA, FGFR, STK11, and KEAP1. Conclusions: In this large, multicenter Turkish real-world cohort, the TGA spectrum broadly mirrors global patterns while revealing local nuances; EGFR mutations were more frequent than expected in SCC, and nationwide NGS adoption is accelerating. Limitations include retrospective design, non-centralized PD-L1 testing, and missing data. Prospective, standardized studies integrating outcomes and resistance mechanisms are warranted to refine regional precision oncology.
1

18 May 2026 in Medicina
Verified
Journal Article
Open access
PDF file
MSMustafa Seyyar
Mustafa Seyyar
PŞPervin Can Şancı
Pervin Can Şancı
ASAbdullah Sakin
Abdullah Sakin
ABAyberk Bayramgil
Ayberk Bayramgil
ÖKÖzgecan Dülgar Kaya
Özgecan Dülgar Kaya
UKUmut Kefeli
Umut Kefeli
Background and Objectives: Perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) is the standard of care for resectable gastric and gastroesophageal junction adenocarcinoma; however, up to 50% of patients develop metastatic recurrence. These patients have prior exposure to platinum and taxane agents, and optimal first-line treatment in the metastatic setting remains undefined. This study aimed to characterize real-world treatment patterns and outcomes in patients progressing after perioperative FLOT, focusing on relapse timing and HER2 status. Materials and Methods: This retrospective, multicenter cohort study included 296 patients from 31 centers across Türkiye, stratified into early relapse (≤6 months, n = 114) and late relapse (>6 months, n = 182) groups. Survival analyses were performed using the Kaplan-Meier method and Cox proportional hazards regression. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Results: Median PFS and OS for the entire cohort were 6 and 9 months, respectively. Early relapsers had significantly shorter median PFS (4 vs. 6 months, p = 0.029) and OS (8 vs. 12 months, p = 0.047); however, early relapse timing did not retain independent prognostic significance on multivariable analysis. No significant difference in PFS or OS was observed between cytotoxic chemotherapy regimens in either relapse group. HER2 positivity was the only independent predictor of improved PFS on multivariable Cox analysis (HR 0.48, 95% CI 0.29–0.81; p = 0.006). In the late relapse group, trastuzumab-based chemotherapy achieved a median PFS of 14 months and OS of 18 months, significantly superior to all cytotoxic regimens (PFS p = 0.007; OS p = 0.029). Conclusions: In patients progressing after perioperative FLOT, cytotoxic chemotherapy regimen selection did not demonstrate a statistically significant survival difference in this retrospective cohort, regardless of relapse timing. HER2 positivity is the dominant predictive biomarker, and trastuzumab-based therapy suggests a potential survival benefit that warrants prospective validation. Comprehensive biomarker profiling at metastatic diagnosis and prospective trials designed for this post-FLOT population are needed to establish evidence-based treatment standards.

27 January 2026 in TURKISH JOURNAL of CLINICS and LABORATORY
Verified
Journal Article
Closed access
AYATİLA YILDIRIM
ATİLA YILDIRIM
MDMustafa Emre Duygulu
Mustafa Emre Duygulu
GTGorkem Turhan
Gorkem Turhan
EKErhan Kaya
Erhan Kaya
MUMehmet Uzun
Mehmet Uzun
Aim: Breast cancer is the most frequently diagnosed cancer and one of the main causes of cancer related death in women worldwide. Around 70% of breast cancer cases are estrogen receptor positive (ER+), and many of these patients benefit from hormone based treatments. However, despite initial responses, a large number of patients eventually develop resistance, especially in the metastatic stage .This study aims to identify and analyze the 100 most cited original research articles related to ESR1-mutant breast cancer, providing insights into publication trends, leading contributors, and thematic focuses in this growing field.Material and Methods: A systematic search was conducted on May 20, 2025, using the Web of Science Core Collection (WoSCC). The top 100 cited original research articles related to ESR1 mutations in breast cancer were selected based on citation count, excluding non-original and non-English papers. Bibliometric mapping was performed using VOSviewer software (v1.6.10).Results: A total of 100 articles published between 2007 and 2024 were analyzed. The most cited article received 919 citations. Most publications and citations originated from the United States. Nature Genetics had the highest citation rate per article, while Clinical Cancer Research had the largest number of top-cited articles. Common keywords included “ESR1,” “breast cancer,” and “resistance.”Conclusion: This bibliometric analysis highlights the foundational and emerging literature on ESR1 mutations in breast cancer. It provides a valuable reference for researchers and clinicians by identifying pivotal studies and mapping the development of this research domain.

15 January 2026
Verified
Book Chapter
Closed access
GTGorkem Turhan
Gorkem Turhan
Meme kanseri, kadınlarda en sık görülen ve en fazla ölüme yol açan kanser türüdür. İleri evre meme kanseri hastalarının bir kısmında visseral kriz (VK) tablosu görülebilmektedir. VK, hızlı organ disfonksiyonu ile karakterize yaşamı tehdit eden bir durumdur ve acil tedavi gerektirir. Mevcut kılavuzlar VK yönetiminde kombinasyon kemoterapisini önerse de, tedavi seçiminde net bir protokol bulunmamaktadır. Retrospektif çalışmalar VK tablosu bulunan hastalarda prognozun kötü olduğunu göstermektedir. VK tedavisinde kombinasyon kemoterapileri standart tedavi olmasına rağmen, hastalarda tolerasyon sorunları ve toksisitelere yol açmaktadır. Son dönemde, CDK4/6 inhibitörlerinin etkinliğini araştıran RIGHT Choice çalışması, Ribosiklib+Endokrin tedavinin kemoterapiye kıyasla daha uzun progresyonsuz sağkalım ve daha iyi tolerabilite sağladığını göstermiştir. Ayrıca, retrospektif veriler, VK tablosunda endokrin tedavi veya anti-HER2 ajan kullanımının kemoterapiye göre daha iyi sonuçlar verebileceğini düşündürmektedir. VK’de tedavi stratejilerini iyileştirmek için antikor-ilaç konjugatları gibi yeni ilaç sınıflarının etkinliğini değerlendiren prospektif çalışmalara ihtiyaç vardır. Ayrıca, güvenilir prognostik faktörlerin eksikliği, aktif tedavi ile palyatif bakım arasında doğru seçim yapmayı güçleştirmektedir.

19 May 2026 in Medicina
Verified
Journal Article
Open access
PDF file
AKAnil Karakayalı
Anil Karakayalı
MSMustafa Seyyar
Mustafa Seyyar
PŞPervin Can Şancı
Pervin Can Şancı
ESElif Sahin
Elif Sahin
BKBerkan Karabuğa
Berkan Karabuğa
KUKazım Uygun
Kazım Uygun
Background and Objectives: Neoadjuvant chemotherapy (NAC) followed by radical cystectomy is the standard of care for eligible patients with locally advanced bladder cancer (LABC). However, adjuvant chemotherapy (AC) remains widely used in real-world practice. Host-related inflammatory and nutritional biomarkers may also influence survival outcomes. This study aimed to compare survival outcomes between NAC and AC and to identify independent prognostic factors for overall survival (OS) and progression-free survival (PFS), with particular emphasis on the Prognostic Nutritional Index (PNI). Methods: This multicenter retrospective study included 262 patients with locally advanced bladder cancer. The median age was 66 years, and 84% of patients were male. Patients were treated with neoadjuvant chemotherapy followed by radical cystectomy or adjuvant chemotherapy after surgery between August 2021 and March 2025. The Prognostic Nutritional Index (PNI) was calculated using pretreatment laboratory values. ROC analysis was used to determine the optimal PNI cut-off for predicting mortality, and the derived threshold (49.97) was applied for stratification in all survival analyses. Survival outcomes were evaluated using the Kaplan–Meier method and compared using the log-rank test. Multivariate Cox proportional hazards regression was used to identify independent prognostic factors. Results: Among 262 patients, 138 (52.7%) received NAC, and 124 (47.3%) received AC. Median follow-up was 33.6 months (95% CI: 29.4–37.8). No statistically significant differences in OS (p = 0.388) or PFS (p = 0.499) were observed between treatment groups. In univariate analyses, nodal stage, pathological complete response (pCR), and PNI were significantly associated with both OS and PFS. In multivariate analysis, low PNI (≤49.97) remained an independent predictor of mortality (HR 1.78, 95% CI 1.04–3.38; p = 0.044), while N3 nodal stage independently predicted disease progression (HR 5.92, 95% CI 1.06–32.84; p = 0.042). Conclusions: In this multicenter real-world cohort, nodal stage and systemic inflammatory-nutritional status were key determinants of prognosis in patients with locally advanced bladder cancer receiving perioperative chemotherapy. PNI emerged as an independent predictor of overall survival, suggesting that host-related biomarkers may improve prognostic stratification beyond traditional clinicopathological factors.

Verified
Journal Article
Open access
PDF file
SSSerhat Sekmek
Serhat Sekmek
AOAYSEL OĞUZ
AYSEL OĞUZ
MEMelek Karakurt Eryılmaz
Melek Karakurt Eryılmaz
MAMurat Araz
Murat Araz
SBSedat Biter
Sedat Biter
GUGokhan Ucar
Gokhan Ucar
Background/Objectives: In this retrospective study, we aimed to compare the efficacy, survival, and toxicity results of induction (IC) or adjuvant (AC) treatment with chemoradiotherapy (CRT) in locally advanced nasopharyngeal cancer (NPC). Methods: A total of 405 patients from 22 different centres in Turkey, belonging to the Turkish Oncology Group (TOG), was included. The primary endpoints were overall survival (OS) and progression-free survival (PFS), and the secondary endpoints were safety and toxicity. Results: The median age of the patients included in the study was 49 (18.2–91.5) years. In total, 298 (73.6%) of the patients were male. Of the 405 patients, 258 (63.7%) received IC and 147 (36.3%) received AC treatment. When OS and PFS analyses were performed in terms of age, gender, T and N stages, pathological features, and treatments received, no effect of any variable on prognosis was observed. For the overall group, the median estimated OS was 137.3 months (the Kaplan–Meier statistical method could not reach the 95% confidence interval [CI]). For the IC group, the median estimated survival was 137.3 months (95% CI: 111.4–163.3), whereas the Kaplan–Meier statistical method could not estimate survival for the AC group. No statistically significant difference was observed between IC and AC groups in terms of OS (p = 0.209) or PFS (p = 0.248). Grade 3–4 side effects were observed in 12% of patients in the IC group and 29.9% of patients in the AC group. Treatment was discontinued due to toxicity in 5 patients (1.9%) in the IC group and 18 patients (12.2%) in the AC group. Conclusion: No difference in OS or PFS was observed between AC and IC treatments. More grade 3–4 side effects were observed in the AC-treated group and early discontinuation rate was higher.